- $27.73m
- $11.71m
- $39.95m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.86 | ||
| Price to Tang. Book | 0.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.69 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -7.2% | ||
| Return on Equity | -12.16% | ||
| Operating Margin | -11.19% | ||
Financial Summary
| Year End 31st May | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 66.15 | 62.66 | 58.59 | 48.87 | 39.95 | n/a | n/a | -7.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -16.89 | -84.12 | -42.14 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BIOQUAL, Inc. is a preclinical contract research organization (CRO) providing comprehensive in vivo and in vitro research services for pharmaceutical, biotechnology, government, and academic organizations. It specializes in research across a range of critical scientific areas, with a focus on infectious and human diseases. It offers comprehensive in vivo and in vitro preclinical research services to both commercial and government clients. Its solutions include research areas, research models, in vitro services, and research solutions. The in vitro services include cell-based assays to evaluate proliferation, viability, apoptosis, viral load, and immunogenicity testing. High-throughput screening enables compound profiling, while immunoassays such as enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunospot (ELISpot), Luminex, Western blot, and flow cytometry deliver detailed analyses of protein expression and immune responses.
Directors
- David Newcomer DRC (48)
- Chander Sarma VPR
- Mark Lewis CHM
- Nancy Madden VAD
- MITCH FRANKLIN VOP
- Hanne Andersen DRC
- David Landon DRC
- Charles Kirk CFO
- Hanne Elyard PRE
- Amy Johnston DRC
- Last Annual
- May 31st, 2026
- Last Interim
- May 31st, 2026
- Incorporated
- January 5th, 1982
- Public Since
- July 14th, 1983
- No. of Employees
- 108
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 894,416
- Address
- 9600 Medical Center Dr #101,, ROCKVILLE, 20850
- Web
- https://bioqual.com
- Phone
- +1 2404047654
- Auditors
- Aprio LLP
Latest News for BIOQ
Upcoming Events for BIOQ
Q2 2027 Bioqual Inc Earnings Release
Q3 2027 Bioqual Inc Earnings Release
Similar to BIOQ
ABPRO Holdings
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adaptin Bio
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
FAQ
As of Today at 18:38 UTC, shares in Bioqual are trading at $31.00. This share price information is delayed by 15 minutes.
Shares in Bioqual last closed at $31.00 and the price had moved by -22.5% over the past 365 days. In terms of relative price strength the Bioqual share price has underperformed the S&P500 Index by -29.69% over the past year.
There is no consensus recommendation for this security.
Find out moreBioqual does not currently pay a dividend.
Bioqual does not currently pay a dividend.
Bioqual does not currently pay a dividend.
To buy shares in Bioqual you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $31.00, shares in Bioqual had a market capitalisation of $27.73m.
Here are the trading details for Bioqual:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BIOQ
Based on an overall assessment of its quality, value and momentum Bioqual is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioqual. Over the past six months, its share price has underperformed the S&P500 Index by -15.92%.
As of the last closing price of $31.00, shares in Bioqual were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bioqual PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $31.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bioqual's management team is headed by:
- David Newcomer - DRC
- Chander Sarma - VPR
- Mark Lewis - CHM
- Nancy Madden - VAD
- MITCH FRANKLIN - VOP
- Hanne Andersen - DRC
- David Landon - DRC
- Charles Kirk - CFO
- Hanne Elyard - PRE
- Amy Johnston - DRC